Alivus Life Q2 FY27 Earnings Call — Analysis (NSE: ALIVUS)
Alivus Life Sciences delivered strong Q2FY27 revenue growth of 16% YoY to ₹682 Cr with EBITDA margins expanding 880 bps YoY to 41.8%, while reiterating full-year FY27 revenue guidance of 10-12% and EBITDA margins of 35-36%.
Result quality: stable — Results context unavailable. Management sentiment: optimistic.
The take
Q2FY27 Revenue from Operations ₹682 Cr ( +16.0% YoY ) . New guidance — FY27 gpl revenue fy27 ₹700 Cr to ₹750 Cr . New story: Solapur Greenfield Expansion and Backward Integ… .
Results
Revenue grew 16% YoY to ₹682 Cr, with gross margin expanding 670 bps YoY to 64.4% and reported EBITDA margin reaching 41.8% (adjusted 39.5%).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from Operations | ₹682 Cr | +16.0% | yoy · Q2FY27 |
| Gross Margin | 64.4% | +670bps | yoy · Q2FY27 |
| EBITDA | ₹285 Cr | +47.0% | yoy · Q2FY27 |
| EBITDA Margin | 41.8% | +880bps | yoy · Q2FY27 |
| Adjusted EBITDA Margin | 39.5% | none · Q2FY27 · excluding one-off income | |
| PAT | ₹197 Cr | yoy · Q2FY27 | |
| PAT Margin | 28.9% | +680bps | yoy · Q2FY27 |
| CDMO Revenue | ₹50 Cr | +80.0% | yoy · Q2FY27 |
| Revenue from Operations | ₹1,322 Cr | +11.1% | yoy · H1FY27 |
| EBITDA Margin | 39.3% | +780bps | yoy · H1FY27 |
| PAT | ₹357 Cr | yoy · H1FY27 | |
| Cash and Cash Equivalents | ₹1,012 Cr | point_in_time · H1FY27 · Sep-26 | |
| Capex | ₹105 Cr | none · Q2FY27 | |
| Capex | ₹190 Cr | none · H1FY27 |
Guidance
Management reiterated FY27 revenue growth guidance of 10% to 12% with EBITDA margins expected in the 35% to 36% range.
What management committed to
- [Alivus Life Sciences] expects full year [FY27] GPL revenues to be around INR700 crores to INR750 crores. — INR700 crores to INR750 crores, FY27
- [Alivus Life Sciences] Phase 1 of the [Solapur facility] is expected to become operational in Q3 of FY27. — Q3FY27
- [Alivus Life Sciences] reiterates [its] FY27 revenue growth guidance of 10% to 12%. — 10% to 12%, FY27
- [Alivus Life Sciences] expects EBITDA margins in the 35% to 36% range in FY27. — 35% to 36%, FY27
- [Alivus Life Sciences] has 5 projects right now that [the company] should execute commercially in flow [chemistry] in about 18 to 24 months. — 5 projects, Q2FY29
- [Alivus Life Sciences] expects [the CDMO business] to double from where it is today in the next 3 to 4 years' time, contributing between 12% to 15% of overall revenues. — double; 12% to 15%, FY31
- [Alivus Life Sciences] expects commercialization of most of [its] high potent portfolio from late FY28 to around FY33-FY34. — FY34
Key themes
Portfolio enrichment and CDMO scale-up
How the narrative shifted
- Portfolio Quality and Margin Expansion: Management highlights that structural shifts toward complex APIs, new product launches, and operating efficiencies are driving sustainable gross and EBITDA margin improvements.
- Solapur Greenfield Expansion and Backward Integration: Solapur greenfield will alleviate intermediate bottlenecks, support cost competitiveness through backward integration, and unlock large-volume CDMO and API opportunities over a 2-3 year horizon.
- CDMO Scaling and Platform Broadening: The company is expanding its CDMO scope beyond basic APIs into intermediates, formulation dossiers, pellets, and flow chemistry to target a broader customer base and double the segment in 3-4 years.
- Managing Cost Escalation and Input Risk: Input cost risks like solvent price surges are mitigated via strategic inventory interventions and fuel switching from natural gas to bio-briquettes.
Operational commentary
- Solapur Greenfield facility Phase 1 is scheduled to become operational in Q3FY27, initially serving backward integration and intermediate requirements before expanding into API supplies following regulatory approvals.
- Construction of the new R&D center at Taloja is on track to be completed early next year.
- CDMO business scale-up is driven by increased volume traction across 5 active projects, with discussions ongoing to add new innovator projects in H1 next fiscal.
- Flow chemistry platform successfully halved COGS on one commercialized product, with 5 additional flow chemistry projects targeted for commercial execution in the next 18 to 24 months.
- HP API pipeline features 30 products representing an addressable market of $86 billion, with 14 validated, 7 in advanced development, and commercial launches expected between late FY28 and FY34.
- Formulation CRO expansion progressing with a targeted pipeline of 25-30 dossiers over 3 years, while evaluating the construction of a dedicated oral solids manufacturing facility over an 18 to 24 month timeframe.
Analyst Q&A
Q. What was the nature of the one-off income in Q2FY27?
The one-off comprised a validation supply of a complex product at high margins plus a one-off income accrual from a customer during the quarter.
Q. Will the higher EBITDA margins sustain into FY28 given the higher GPL mix in H2?
Management indicated an aim to achieve similar margins to FY27, with a baseline floor of 30% to 32% if adverse conditions occur, supported by launch momentum and cost interventions.
Q. Are capacity constraints hindering CDMO project additions?
Large intermediate CDMO projects were previously not entertained due to intermediate capacity constraints, but the upcoming Solapur facility will enable the company to aggressively pursue larger intermediate and API CDMO volumes.
Q. What is the strategy regarding manufacturing for the formulation and oncology pipeline?
Management intends to utilize third-party manufacturers initially but strongly leans toward constructing an in-house oral solids manufacturing facility in 18 to 24 months to protect IP and ensure quality.
Research and educational content only. Not investment advice.